
Opinion|Videos|June 21, 2024
Examining Molecular Testing in Metastatic Urothelial Cancer: Present and Future
Author(s)Pedro Barata, MD, MSc, FACP
A key opinion leader offers a comprehensive overview of the present landscape of molecular testing in metastatic urothelial cancer, elaborating on how advancements in molecular testing have shaped his clinical practice and expressing optimism for their future incorporation into the National Comprehensive Cancer Network (NCCN) guidelines.
Advertisement
Episodes in this series

- Please provide an overview of the current state and evolution of molecular testing in metastatic urothelial cancer.
- How has molecular testing and targeted agents changed your practice in treating mUC?
- Discuss NCCN recommendations and if/how your practice aligns.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma
4
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
5


















